• DOI:10.1038/nrd1958
Corpus ID: 21379258

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

@article{Lipton2006ParadigmSI,
  title={Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond},
  author={S. Lipton},
  journal={Nature Reviews Drug Discovery},
  year={2006},
  volume={5},
  pages={160-170}
}

• S. Lipton
• Published 2006
• Chemistry, Medicine
• Nature Reviews Drug Discovery

Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological… Expand

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed